(Q53830656)

20 May 2018

editorial

0 references

title

Pharmacogenomics of cytarabine in childhood leukemia. (English)

1 reference

20 May 2018

1 reference

1 reference

1 reference

Jatinder K Lamba

1

1 reference

20 May 2018

publication date

1 December 2011

1 reference

20 May 2018

published in

Pharmacogenomics

1 reference

20 May 2018

volume

12

1 reference

20 May 2018

issue

12

1 reference

20 May 2018

page(s)

1629-1632

1 reference

20 May 2018

Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Genetic factors influencing cytarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.148

21 January 2018

Identifiers

DOI

10.2217/PGS.11.148

1 reference

20 May 2018

1 reference

20 May 2018